Consolidated balance sheet
|
in CHF 1 000 |
|
Notes |
|
31.03.2022 |
|
31.12.2021 |
|
Current assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
1 635 |
|
2 835 |
|
Securities |
|
4 |
|
3 118 719 |
|
3 641 112 |
|
Other assets |
|
|
|
160 |
|
135 |
|
|
|
|
|
3 120 514 |
|
3 644 082 |
|
Total assets |
|
|
|
3 120 514 |
|
3 644 082 |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Short-term borrowings from banks |
|
5 |
|
355 000 |
|
355 000 |
|
Other short-term liabilities |
|
|
|
4 458 |
|
5 431 |
|
Tax liabilities |
|
|
|
178 |
|
158 |
|
|
|
|
|
359 636 |
|
360 589 |
|
Total liabilities |
|
|
|
359 636 |
|
360 589 |
|
|
|
|
|
|
|
|
|
Shareholders' equity |
|
|
|
|
|
|
|
Share capital |
|
6 |
|
11 080 |
|
11 080 |
|
Treasury shares |
|
6 |
|
(19 716) |
|
(9 205) |
|
Retained earnings |
|
|
|
2 769 514 |
|
3 281 618 |
|
|
|
|
|
2 760 878 |
|
3 283 493 |
|
Total liabilities and shareholders' equity |
|
|
|
3 120 514 |
|
3 644 082 |
|
|
|
|
|
|
|
|
|
Net asset value per share in CHF |
|
|
|
50.10 |
|
59.40 |
The notes are an integral part of the condensed consolidated interim financial statements.
The condensed consolidated interim financial statements were approved by the Board of Directors of BB Biotech AG on April 19, 2022.